Pharma’s global reset: Economic and strategic shifts in manufacturing, pricing, and innovation
After months of disruption and speculation, is the global pharmaceutical industry entering a new era? With the White House’s recent launch of the TrumpRx platform and a landmark deal with Pfizer to implement “most-favoured-nation” pricing, the US is signalling a dramatic shift in how it approaches drug pricing, manufacturing, and global trade.
This webinar brings together economic and strategic experts from ING to unpack the implications of these developments for the global pharma sector. We’ll explore how the US is reshaping its pharmaceutical policy, and what this means for Europe, the continued rise of China, and the future of generic drug production.
Join us to understand the forces reshaping the pharmaceutical value chain - and how to stay ahead.
Speakers
This event has been prepared by ING solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not constitute investment recommendation, and nor is it investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Read more